Table 2.

Chlamydia trachomatis and Neisseria gonorrhoeae prevalence at final visit

	DMPA-IM group		Copper IUD group		LNG implant group		DMPA-IM vs copper IUD		DMPA-IM vs LNG implant		Copper IUD vs LNG implant
	Events/ women	PP (95% CI)	Events/ women	PP (95% CI)	Events/ women	PP (95% CI)	PR (95% CI)	P value	PR (95% CI)	P value	PR (95% CI)	P value
Chlamydia trachomatis
As randomised†	327/2361	13.85 (12.52 to 15.32)	378/2456	15.39 (14.03 to 16.89)	412/2452	16.80 (15.39 to 18.35)	0.9 (0.79 to 1.04)	0.144	0.83 (0.72 to 0.95)	0.005	0.92 (0.81 to 1.04)	0.178
Continuous use‡	221/1686	13.11 (11.59 to 14.82)	309/1995	15.49 (13.98 to 17.16)	377/2139	17.63 (16.08 to 19.32)	0.86 (0.74 to 1.01)	0.062	0.77 (0.66 to 0.89)	0.001	0.89 (0.78 to 1.02)	0.093
Neisseria gonorrhoeae
As randomised†	91/2361	3.85 (3.15 to 4.71)	141/2456	5.74 (4.89 to 6.74)	120/2451	4.90 (4.11 to 5.83)	0.67 (0.52 to 0.87)	0.002	0.79 (0.61 to 1.03)	0.085	1.18 (0.93 to 1.49)	0.175
Continuous use‡	64/1686	3.80 (2.99 to 4.83)	125/ 1995	6.27 (5.29 to 7.42)	110/2138	5.14 (4.29 to 6.17)	0.67 (0.49 to 0.90)	0.007	0.75 (0.56 to 1.02)	0.064	1.13 (0.87 to 1.46)	0.318

*P value is for whether PR differs by subgroup. Subgroup-specific PRs are provided with 95% CIs.

†Adjusted for site only.

‡C. trachomatis analysis: adjusted for age group and baseline C. trachomatis status; N. gonorrhoeae analysis: adjusted for final visit HIV status and total number of pelvic examinations during the study. C. trachomatis analysis: adjusted for age group and baseline C. trachomatis status; N. gonorrhoeae analysis: adjusted for final visit HIV status and total number of pelvic exams during the study.

DMPA-IM, intramuscular depot medroxyprogesterone acetate; IUD, intrauterine device; LNG, levonorgestrel; PP, point prevalence; PR, prevalence ratio.;